Advertisement DrugDev centralizes new SaaS solutions development for clinical research - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

DrugDev centralizes new SaaS solutions development for clinical research

DrugDev is putting out a call to SaaS developers in the Boston area to join the team behind the award-winning, cloud-based software platform that enables clinical trial sponsors, CROs and sites to do more clinical trials together.

The global clinical trial technology company has centralized development of its SaaS solutions in its Boston office due to the area’s unique combination of expert development talent, biopharmaceutical focus and entrepreneurial spirit.

DrugDev is currently offering $1500 (for personal use or for a favorite charity) for any referral that leads to a successful new hire managed from our Boston area office in Newton, MA. Review terms and conditions on our website.

Clinical trials are among the most important activities performed worldwide, yet the technology behind them has historically lagged significantly behind other industries – leading to inefficient and costly processes which delay or prevent many potentially helpful drugs from reaching patients.

DrugDev’s innovative solutions are transforming the clinical research process through industry-wide collaboration, standardization and a beautiful technology experience.

"Our goal is to make DrugDev the first name people think of when they hear about pharmaceutical technology," said Ezra Freedman, Chief Technology Officer of DrugDev TrialNetworks.

"This is an exciting time for developers who are passionate about creating solutions with a significant societal impact to join our team. We offer excellent mentorship and career advancement opportunities, a collaborative and friendly culture, opportunities to work with leading web-based platforms, and contribute to open-source architecture – as well as a fairly competitive ping pong scene."

Freedman co-founded TrialNetworks (acquired by DrugDev in 2014) with Eric Silberstein and their colleague Dr. Vivek Murthy, who now serves as Surgeon General of the United States of America.

Demand for DrugDev solutions is soaring, spurred by client adoption of new solutions as well as major industry initiatives including the TransCelerate Investigator Registry (launching this year). The Boston office in particular has doubled its office space – twice – and tripled its development team during the past 18 months, with continued expansion planned.

Added Kate Flathers, who joined DrugDev as Director of Technology after a sustained leadership role at Oracle, "Developing technology is fun, and it’s even better when it adds meaningful value. We are passionate about the need to speed drug development so companies can do what they do best -getting drugs to patients who need them – faster.

"Our software is already in use by tens of thousands of users worldwide, and we look forward to bringing them new SaaS solutions as we continue to expand DrugDev technology into exciting new areas of clinical research."